Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

External validation of the early-stage classic Hodgkin lymphoma (cHL) international prognostication index (E-HIPI) in the german Hodgkin study group (GHSG) unfavorable clinical trials

Blood (2025) 146 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2025-1845

Published: 2025

Journal Articles

Randomised Phase II study of acalabrutinib in combination with R-CHOP treatment for diffuse large B-cell lymphoma confirms safety and unimpaired treatment delivery

Blood (2025) 146 (Supplement 1): 5459.

https://doi.org/10.1182/blood-2025-5459

Published: 2025

Journal Articles

PET-adaptive beacopp- versus ABVD-based therapies for advanced-stage (AS) classic Hodgkin lymphoma (cHL): Survival comparisons leveraging a multi-state model and analyzing the impact of a-hipi scores across the disease course

Blood (2025) 146 (Supplement 1): 129.

https://doi.org/10.1182/blood-2025-129

Published: 2025

Journal Articles

Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium

Blood (2024) 144 (Supplement 1): 567.

https://doi.org/10.1182/blood-2024-207439

Published: 2024

Journal Articles

PET-Based Prognostic Stratification in Primary Mediastinal B-Cell Lymphoma Using the SUV≥4 Segmentation Threshold: A Comparative Analysis of Contouring Methods in the IELSG37 Trial Cohort

Luca Ceriani, Lisa Milan, Maria Cristina Pirosa, Alice Di Rocco, Teresa Ruberto, Luciano Cascione, Peter Johnson, Andrew J. Davies, Maurizio Martelli, Emanuele Zucca

Blood (2024) 144 (Supplement 1): 1712.

https://doi.org/10.1182/blood-2024-206784

Published: 2024

Journal Articles

Involved Field Radiotherapy Versus No Further Treatment in Patients with Newly Diagnosed Stage 1A or 2A Hodgkin Lymphoma and a ‘Negative’ PET Scan after 3 Cycles ABVD. Survival and Cause of Death after a Median of 16 Years Follow-up in the UK RAPID Trial

John Radford, Joanna Williams, Darren Edwards, Ruth Pettengell, Peter Johnson, Peter Hoskin, Timothy Illidge, Nicholas Counsell

Blood (2024) 144 (Supplement 1): 457.

https://doi.org/10.1182/blood-2024-200662

Published: 2024

Journal Articles

Identification of Risk Categories from the Advanced-Stage Hodgkin International Prognostic Index (A-HIPI) Model: A Detailed Analysis from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Matthew J. Maurer, Susan K Parsons, Jenica Upshaw, Jonathan W. Friedberg, Andrea Gallamini, Massimo Federico, Eliza A Hawkes, David Hodgson, Peter Johnson, Brian K. Link, Kerry J. Savage, Pier Luigi Zinzani, Andrew M Evens

Blood (2023) 142 (Supplement 1): 3067.

https://doi.org/10.1182/blood-2023-175079

Published: 2023

Journal Articles

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Andrew M Evens, Angie Mae Rodday, Matthew J. Maurer, Ranjana H. Advani, Marc Andre, Andrea Gallamini, Annette E. Hay, David Hodgson, Richard T. Hoppe, Martin Hutchings, Peter Johnson, Brian K. Link, Stephen Opat, John M. Raemaekers, Jenica Upshaw, Qingyan Xiang, Nicholas Counsell, Susan K Parsons, John Radford

Blood (2023) 142 (Supplement 1): 3058.

https://doi.org/10.1182/blood-2023-173320

Published: 2023

Journal Articles

Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial

Elizabeth H Phillips, Amy A Kirkwood, Christina Hague, Jorgen Vestbo, Massimo Federico, Francesco D'Amore, Alexander Fossa, Judith Trotman, Leanne Berkahn, Daniel L. Molin, Stefano Luminari, Sally F Barrington, Peter Johnson, John Radford

Blood (2023) 142 (Supplement 1): 612.

https://doi.org/10.1182/blood-2023-185818

Published: 2023

Journal Articles

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Emanuele Zucca, Luca Ceriani, Andrew S. Davies, Giovannino Ciccone, Umberto Ricardi, Alice Di Rocco, Iryna Kryachok, Barbara Botto, Monica Balzarotti, Alessandra Tucci, Vittorio Ruggero Zilioli, Sara Usai, Luca Arcaini, Elsa Pennese, Anna Dabrowska-Iwanicka, Andrés José María Ferreri, Franceso Merli, Wei Li Zhao, David Hodgson, Codruta Ionescu, Luigi Rigacci, Claudia Cellini, Caterina Stelitano, Stefano Volpetti, Carla Minoia, Michele Spina, Alexander Fossa, George Mikhaeel, Kate Cwynarski, Andrea Janikova, Yana Stepanishyna, Mats Jerkeman, Andreas Huettmann, Maria Gomes da Silva, Don A. Stevens, Sally F Barrington, Bogdan Małkowski, Ur Metser, Annibale Versari, Stephane Chauvie, Oreste Bagni, Kelly Cozens, Sonia Perticone, Nicoletta Ielmini, Letizia Deantonio, Jan Walewski, Marek Trneny, Mary Gospodarowicz, Franco Cavalli, Peter Johnson, Maurizio Martelli

Blood (2023) 142 (Supplement 1): 1718.

https://doi.org/10.1182/blood-2023-174093

Published: 2023

Journal Articles

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Blood (2022) 140 (Supplement 1): 1770–1772.

https://doi.org/10.1182/blood-2022-159976

Published: 2022

Journal Articles

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew J Davies, Josh Caddy, Katy McLaughlin, Christopher Wignall, Robert Waugh, Graham P. Collins, Louise Stanton, Geoff N Saunders, Thomas Cummin, Anna Schuh, Kirit M. Ardeshna, Andrew K. McMillan, John Radford, David John Lewis, Adam R Coleman, Gareth Griffiths, Cathy Burton, Sharon Barrans, Peter Johnson

Blood (2022) 140 (Supplement 1): 9478–9479.

https://doi.org/10.1182/blood-2022-163499

Published: 2022

Journal Articles

Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)

Joanna Hack, Inês Ralha, Sam Wilding, Louise Stanton, Josh Caddy, Sharon Barrans, Christoph Mamot, Urban Novak, Cathy Burton, Pamela McKay, Gavin Campbell, Andrew Davies, Peter Johnson

Blood (2022) 140 (Supplement 1): 6648–6649.

https://doi.org/10.1182/blood-2022-159442

Published: 2022

Journal Articles

Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy

Stefano Luminari, Alexander Fosså, Judith Trotman, Daniel Molin, Francesco Annibale d'Amore, Gunilla Enblad, Leanne Berkahn, Sally F Barrington, John Radford, Massimo Federico, Amy A. Kirkwood, Peter Johnson

Blood (2022) 140 (Supplement 1): 766–767.

https://doi.org/10.1182/blood-2022-162780

Published: 2022

Journal Articles

Development and Validation of the a dvanced-Stage H odgkin Lymphoma (HL) I nternational P rognostication I ndex (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Angie Mae Rodday, Susan K. Parsons, Jonathan W. Friedberg, Andrea Gallamini, Eliza Hawkes, David C. Hodgson, Peter Johnson, Brian K. Link, Eric Mou, Kerry J. Savage, Jenica Upshaw, Pier Luigi Zinzani, Matthew J. Maurer, Andrew M. Evens

Blood (2022) 140 (Supplement 1): 760–762.

https://doi.org/10.1182/blood-2022-164720

Published: 2022

Journal Articles

Does R-IPI Remain Predictive of Relapse Risk for Patients with DLBCL Achieving a Complete Remission with Frontline Therapy: Landmark Analysis of Two Large Prospective Clinical Trials

Dima El-Sharkawi, Tasneem Elnafie, Sarah Thompson, Louise Stanton, Nicholas Counsell, Amit Sud, Ian Chau, Bhupinder Sharma, Peter Johnson, David C. Linch, Sunil Iyengar, Andrew Davies, David Cunningham

Blood (2022) 140 (Supplement 1): 7908–7909.

https://doi.org/10.1182/blood-2022-167852

Published: 2022

Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

Tycel Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Peter Johnson

Blood (2021) 138 (Supplement 1): 44.

https://doi.org/10.1182/blood-2021-147778

Published: 2021

Journal Articles

Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E

Jack Fisher, Christopher J. Walker, Peter Johnson, Mark S Cragg, Francesco Forconi, Yosef Landesman, Salim I Khakoo, Matthew D Blunt

Blood (2021) 138 (Supplement 1): 2411.

https://doi.org/10.1182/blood-2021-144836

Published: 2021

Journal Articles

Characterising Tumour and Microenvironmental Responses to R-CHOP in Immunocompetent Mouse Models of DLBCL

Bernard D Maybury, Findlay Bewicke-Copley, Peter Johnson, Jude Fitzgibbon, Dinis Pedro Calado

Blood (2021) 138 (Supplement 1): 2401.

https://doi.org/10.1182/blood-2021-152318

Published: 2021

Journal Articles

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

Blood (2021) 138 (5): 370–381.

https://doi.org/10.1182/blood.2020008743

Published: 2021

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

External validation of the early-stage classic Hodgkin lymphoma (cHL) international prognostication index (E-HIPI) in the german Hodgkin study group (GHSG) unfavorable clinical trials

Randomised Phase II study of acalabrutinib in combination with R-CHOP treatment for diffuse large B-cell lymphoma confirms safety and unimpaired treatment delivery

PET-adaptive beacopp- versus ABVD-based therapies for advanced-stage (AS) classic Hodgkin lymphoma (cHL): Survival comparisons leveraging a multi-state model and analyzing the impact of a-hipi scores across the disease course

Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium

PET-Based Prognostic Stratification in Primary Mediastinal B-Cell Lymphoma Using the SUV≥4 Segmentation Threshold: A Comparative Analysis of Contouring Methods in the IELSG37 Trial Cohort

Involved Field Radiotherapy Versus No Further Treatment in Patients with Newly Diagnosed Stage 1A or 2A Hodgkin Lymphoma and a ‘Negative’ PET Scan after 3 Cycles ABVD. Survival and Cause of Death after a Median of 16 Years Follow-up in the UK RAPID Trial

Identification of Risk Categories from the Advanced-Stage Hodgkin International Prognostic Index (A-HIPI) Model: A Detailed Analysis from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)

Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy

Development and Validation of the a dvanced-Stage H odgkin Lymphoma (HL) I nternational P rognostication I ndex (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Does R-IPI Remain Predictive of Relapse Risk for Patients with DLBCL Achieving a Complete Remission with Frontline Therapy: Landmark Analysis of Two Large Prospective Clinical Trials

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E

Characterising Tumour and Microenvironmental Responses to R-CHOP in Immunocompetent Mouse Models of DLBCL

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only